Table 4.
Mean numbers of office visits, ophthalmologist visits, and OCT and fluorescein angiography examinations in 12 months, by diagnosis group and cohort
| Index cohorta | Office visitsb | Ophthalmologist visitsc | OCT examinationsd | Fluorescein angiography examinationsd |
|---|---|---|---|---|
| BRVO | ||||
| 2008 (n=148) | 16.6 | 5.1 | 3.7 | 1.2 |
| 2009 (n=221) | 17.4 | 5.3 | 3.9 | 1.1 |
| 2010 (n=306) | 17.3 | 5.6 | 3.9 | 0.9 |
| CRVO | ||||
| 2008 (n=120) | 20.5 | 6.5 | 3.6 | 0.7 |
| 2009 (n=172) | 20.4 | 5.8 | 3.8 | 1.0 |
| 2010 (n=188) | 19.1 | 5.9 | 3.4 | 0.8 |
| DME | ||||
| 2008 (n=338) | 23.7 | 4.4 | 3.1 | 0.9 |
| 2009 (n=560) | 24.8 | 4.8 | 3.8 | 1.1 |
| 2010 (n=1,009) | 25.0 | 5.3 | 3.6 | 1.0 |
Notes:
a
Year of first bevacizumab injection (2008, 2009, or 2010)
b
defined as the number of days the patient had one or more outpatient claims
c
broadly defined as the number of days on which the patient had one or more outpatient claims for the index diagnosis with the provider specialty of “ophthalmologist/optometrist” or received an OCT examination and/or an intravitreal injection
d
capped at a maximum of two per patient per day.
Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; DME, diabetic macular edema; OCT, optical coherence tomography.